Online inquiry

IVTScrip™ mRNA-Anti-CD274, CS-1001(Cap 0, Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ6288MR)

This product GTTS-WQ6288MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & Pseudo-UTP. It ecodes the monoclonal antibody that targets CD274 gene. The antibody can be applied in Cancers, non-small cell lung (NSCLC), T cell lymphoma research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_001267706.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 29126
UniProt ID Q9NZQ7
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD274, CS-1001(Cap 0, Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ6288MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ12828MR IVTScrip™ mRNA-Anti-FZD10, ONC-005(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ONC-005
GTTS-WQ12937MR IVTScrip™ mRNA-Anti-MUC1, PankoMab(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA PankoMab
GTTS-WQ14799MR IVTScrip™ mRNA-Anti-CD70, SGN-70(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA SGN-70
GTTS-WQ10855MR IVTScrip™ mRNA-Anti-FOLR1, M9346A(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA M9346A
GTTS-WQ9845MR IVTScrip™ mRNA-Anti-ICOS, JTX-2011(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA JTX-2011
GTTS-WQ5948MR IVTScrip™ mRNA-Anti-IGHE, CL-2C(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA CL-2C
GTTS-WQ12334MR IVTScrip™ mRNA-Anti-TIGIT, MTIG-7192-A(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA MTIG-7192-A
GTTS-WQ9275MR IVTScrip™ mRNA-Anti-TACSTD2, IMMU-132(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA IMMU-132
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW